二甲双胍对非糖尿病肥胖的卵巢癌患者化疗耐药性和生存期的影响#br#

The effect of HLA-DQB1-AS1 regulating the expression of miRNA-205-5p on the proliferation,migration and invasion of cervical cancer

Objective?To analyze the effects of metformin on chemotherapy resistance and survival time of non-diabetic obese patients with ovarian cancer. Methods?Clinical data of 150 patients with ovarian cancer complicated with non-diabetic obesity treated in Department of Gynecologic Oncology of Linyi Cancer Hospital were retrospectively analyzed between January 2016 and November 2018. Patients were divided into groups A and B and placebo group (each n=50) according to different treatments. Chemotherapy sensitivity and drug resistance, serum human insulin-like growth factor 1 (IGF-1), human insulin-like growth factor receptor (IGF-1R), serine/threonine protein kinase (AKT) and incidence rates of drug side effects during treatment were compared. After 3 years of follow-up, survival time was compared among patients with different treatment methods. Results?Drug resistance rate of 24.00% in group A and 18.00% in group B were both lower than 44.00% in placebo group (P<0.05). After treatment, IGF-1, IGF-1R and AKT in groups A and B were lower than those in placebo group, and above indicators in group B were lower than those in group A and placebo group (P<0.05). There were no significant differences in incidence rates of side effects among three groups of different drug treatment regimens (P>0.05). Overall survival rate of 76.00% (38/50) in group A and 82.00% (41/50) in group B, were higher than 68.00% (34/50) in placebo group (P<0.05). Median survival time of 32 months in group B was longer than 29 months in group A and 25 months in placebo group. Conclusion?Metformin can promote tumor cell apoptosis, improve tumor microenvironment, reduce drug resistance and prolong survival time by regulating levels of IGF-1 and IGF-1R in non-diabetic obese patients with ovarian cancer.